Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea.

Blood advances·2026

Same author

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026

Same author

Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report.

Pediatrics·2026

Same author

Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia.

BMC research notes·2026

Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026

Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

Hydroxyurea for children with sickle cell disease.

Matthew M Heeney¹, Russell E Ware

¹Harvard Medical School, Boston, MA, USA. matthew.heeney@childrens.harvard.edu

Pediatric Clinics of North America

|April 3, 2008

Summary

Hydroxyurea therapy shows promise for improving sickle cell disease (SCD) in children. While effective and safe for managing sickling and organ damage, its long-term risks require further study.

Area of Science:

Pediatric Hematology
Pharmacology
Genetic Blood Disorders

Background:

Sickle cell disease (SCD) is a serious inherited blood disorder affecting children.
Current treatments aim to manage symptoms and prevent complications.
Hydroxyurea is a key medication with known benefits in SCD management.

Purpose of the Study:

To evaluate the efficacy and safety of hydroxyurea in pediatric SCD.
To understand hydroxyurea's mechanisms in addressing SCD pathophysiology.
To highlight the underutilization of this effective therapy.

Main Methods:

Review of existing clinical data and therapeutic applications of hydroxyurea in pediatric SCD.
Analysis of hydroxyurea's pharmacologic actions on sickling and hemolysis.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Experiment Videos

Last Updated: Jul 6, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Assessment of documented side effects and therapeutic window.

Main Results:

Hydroxyurea effectively targets key SCD pathways like sickling, vaso-occlusion, and hemolysis.
The drug is generally well-tolerated with a wide therapeutic window.
Limited data exist on its long-term organ protective effects and risks.

Conclusions:

Hydroxyurea is an effective, albeit underutilized, therapeutic option for children with SCD.
Further research, including ongoing clinical trials, is needed to fully define long-term risks and benefits.
Optimizing hydroxyurea use can significantly improve the clinical course of pediatric SCD.